Rectal cancer chemotherapy regimen

The chemotherapy regimen for rectal cancer includes classic chemotherapy regimens, which are mainly based on 5-fluorouracil or capecitabine. Capecitabine is an improved preparation of 5-fluorouracil. Classic chemotherapy regimens include: capecitabine plus oxaliplatin, or oxaliplatin plus 5-fluorouracil combined with calcium folinate, or 5-fluorouracil combined with calcium folic acid and irinotecan radiotherapy. These three are classic chemotherapy regimens. With the emergence of molecular targeted therapeutic drugs, for advanced rectal cancer, there are generally a variety of diversified treatment options, including 5-fluorouracil or capecitabine as the basis and combined with bevacizumab or citocillin.

1. After surgery, rectal cancer needs to be treated with intravenous radiotherapy according to the status of lymph node metastasis. Common chemotherapy regimens include fluorouracil and leucovorin. If the patient has significant distant metastasis or is in the advanced stage of rectal cancer, oxaliplatin can also be used in combination. The actual administration method is different. You can choose to inject once every 5 days or pump injection every 3 weeks.

2. If the previous treatment plan fails, irinotecan can be replaced with intravenous radiotherapy in combination with calcium folinate and fluorouracil. Because irinotecan has relatively large side effects, especially gastrointestinal reactions, during the treatment period, attention should be paid to the use of liver and kidney-nourishing drugs, as well as the use of drugs that protect the gastrointestinal mucosa and stop vomiting, and the changes in liver and kidney function indicators should be monitored.

3. The chemotherapy regimen for rectal cancer is generally a fluorouracil-based chemotherapy regimen, such as the FOLFOX regimen, which is oxaliplatin plus fluorouracil, and then there is the capecitabine plus fluorouracil regimen. The most commonly used one now is oxaliplatin plus Xeloda for oral administration. If the disease is relatively advanced, genetic testing can be combined with radiotherapy and targeted drug therapy, so that the patient's prognosis will be better.